Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Novel flu vaccine shows promise in mice

27.05.2003


If successful in humans, vaccine could eliminate annual flu shot



Globally, the influenza virus, or flu, is thought to cause between three and five million cases of severe illness and between 250,000 and 500,000 deaths annually, according to the World Health Organization. New strains of the virus emerge each year, so that the U.S. Centers for Disease Control and other public health services must produce and distribute a new vaccine against the new flu strains each year. And each year, people seeking to avoid a flu infection must arrange to receive a flu shot - rarely a pleasant experience - from their doctor or other health-care provider. Also, the effectiveness of the vaccine is known to decline in the elderly, a population for whom flu infections can be particularly dangerous.

A new prototype vaccine developed by researchers at The Wistar Institute, however, might be able to protect recipients not only against this year’s strains of the virus, but also against those yet to come, possibly eliminating the need for an annual shot. In fact, because the vaccine would be administered as a nasal spray, it could eliminate the need for a shot of any kind. A report on the new findings appears in the June 2 issue of the journal Vaccine.


"Current vaccines are quite effective, but they are based on regions of the virus that mutate rapidly, so health officials are constantly faced with the problem of updating the vaccines," says Walter Gerhard, M.D., senior author on the Vaccine report and a professor in the immunology program at The Wistar Institute. "A vaccine directed against a more stable region of the virus would offer important public-health advantages, and this is what we are hoping to be able to develop."

Current flu vaccines trigger an immune response to a pair of prominent viral-coat proteins that mutate constantly, which is the reason last year’s flu vaccine is ineffective against this year’s flu strains. The experimental vaccine contains an engineered peptide that mimics a third, smaller viral-coat protein called M2 that remains largely constant from year to year.

Mice vaccinated with the vaccine generated a strong antibody response against M2. In fact, the mice generated a more powerful antibody response to the vaccine than to infections by the flu virus itself, according to Gerhard.

"We saw a significant antibody response to our peptide vaccine," he says. "Actually, the response was much stronger than what we saw in mice recovering from infections, which was surprising. This may be meaningful in terms of the potential effectiveness of the vaccine as we go forward."

The experimental vaccine was administered twice intranasally to mice. After vaccination, a steep rise in M2-specific antibodies was seen in blood samples from the mice, and the mice exhibited significant resistance to viral replication in the respiratory tract.

Ongoing experiments in the Gerhard laboratory are exploring the questions of how and why the new flu vaccine is able to produce a stronger antibody response than infections, which are generally considered the best way to generate resistance to any pathogen.

Also, Gerhard is looking into whether the M2 element of the virus might begin to mutate in the presence of the anti-M2 antibodies generated by the new vaccine. His concern is that the observed viral stability in the M2 region of the flu virus may simply be a reflection of the fact that the immune system does not mount a vigorous response to it, so that evolutionary pressure on that region of the virus is not great.

"Among human influenza virus strains, there is little variation in the M2 region," Gerhard says. "That could be due to the fact that humans do not generate a significant antibody response to it, so that the virus does not need to change to escape those antibodies."

Wistar associate professor Laszlo Otvos, Jr., Ph.D., collaborated on the study. Krystyna Mozdzanowska was the lead author. The remaining coauthors, all Wistar-based, are JingQi Feng, Mark Eid, Goran Kragol, and Mare Cudic.

Support for the research was provided by the National Institutes of Health.


The Wistar Institute is an independent nonprofit biomedical research institution dedicated to discovering the causes and cures for major diseases, including cancer, cardiovascular disease, autoimmune disorders, and infectious diseases. Founded in 1892 as the first institution of its kind in the nation, The Wistar Institute today is a National Cancer Institute-designated Cancer Center - one of only eight focused on basic research. Discoveries at Wistar have led to the development of vaccines for such diseases as rabies and rubella, the identification of genes associated with breast, lung, and prostate cancer, and the development of monoclonal antibodies and other significant research technologies and tools.

Franklin Hoke | EurekAlert!
Further information:
http://www.wistar.upenn.edu/

More articles from Health and Medicine:

nachricht Finding new clues to brain cancer treatment
21.02.2020 | Case Western Reserve University

nachricht UIC researchers find unique organ-specific signature profiles for blood vessel cells
18.02.2020 | University of Illinois at Chicago

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A step towards controlling spin-dependent petahertz electronics by material defects

The operational speed of semiconductors in various electronic and optoelectronic devices is limited to several gigahertz (a billion oscillations per second). This constrains the upper limit of the operational speed of computing. Now researchers from the Max Planck Institute for the Structure and Dynamics of Matter in Hamburg, Germany, and the Indian Institute of Technology in Bombay have explained how these processes can be sped up through the use of light waves and defected solid materials.

Light waves perform several hundred trillion oscillations per second. Hence, it is natural to envision employing light oscillations to drive the electronic...

Im Focus: Freiburg researcher investigate the origins of surface texture

Most natural and artificial surfaces are rough: metals and even glasses that appear smooth to the naked eye can look like jagged mountain ranges under the microscope. There is currently no uniform theory about the origin of this roughness despite it being observed on all scales, from the atomic to the tectonic. Scientists suspect that the rough surface is formed by irreversible plastic deformation that occurs in many processes of mechanical machining of components such as milling.

Prof. Dr. Lars Pastewka from the Simulation group at the Department of Microsystems Engineering at the University of Freiburg and his team have simulated such...

Im Focus: Skyrmions like it hot: Spin structures are controllable even at high temperatures

Investigation of the temperature dependence of the skyrmion Hall effect reveals further insights into possible new data storage devices

The joint research project of Johannes Gutenberg University Mainz (JGU) and the Massachusetts Institute of Technology (MIT) that had previously demonstrated...

Im Focus: Making the internet more energy efficient through systemic optimization

Researchers at Chalmers University of Technology, Sweden, recently completed a 5-year research project looking at how to make fibre optic communications systems more energy efficient. Among their proposals are smart, error-correcting data chip circuits, which they refined to be 10 times less energy consumptive. The project has yielded several scientific articles, in publications including Nature Communications.

Streaming films and music, scrolling through social media, and using cloud-based storage services are everyday activities now.

Im Focus: New synthesis methods enhance 3D chemical space for drug discovery

After helping develop a new approach for organic synthesis -- carbon-hydrogen functionalization -- scientists at Emory University are now showing how this approach may apply to drug discovery. Nature Catalysis published their most recent work -- a streamlined process for making a three-dimensional scaffold of keen interest to the pharmaceutical industry.

"Our tools open up whole new chemical space for potential drug targets," says Huw Davies, Emory professor of organic chemistry and senior author of the paper.

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

70th Lindau Nobel Laureate Meeting: Around 70 Laureates set to meet with young scientists from approx. 100 countries

12.02.2020 | Event News

11th Advanced Battery Power Conference, March 24-25, 2020 in Münster/Germany

16.01.2020 | Event News

Laser Colloquium Hydrogen LKH2: fast and reliable fuel cell manufacturing

15.01.2020 | Event News

 
Latest News

Active droplets

21.02.2020 | Medical Engineering

Finding new clues to brain cancer treatment

21.02.2020 | Health and Medicine

Beyond the brim, Sombrero Galaxy's halo suggests turbulent past

21.02.2020 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>